From Investing.com: 2024-07-29 03:21:04

Sandoz Group shares rise after Barclays initiates coverage with “Overweight” rating and CHF 45 price target, citing optimism in Generics and Biosimilars divisions. Analysts highlight Biosimilars pipeline as key growth driver, foreseeing substantial revenue growth from successful launches and robust product pipeline. Company’s strong cash generation and debt profile support organic and inorganic growth opportunities. Despite impressive post-spin-off performance, stock valuation seen as undervalued compared to peers. Market to closely watch for strategic investor event and biosimilar launches. Growth potential noted, along with risks from competition, pricing pressure, and regulations.



Read more at Investing.com: Sandoz shares rise after Barclays initiates coverage with “Overweight” rating By Investing.com